Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The insulin-like growth factor-binding protein complex acid-labile subunit (IGFALS), commonly referred to as the acid-labile subunit (ALS), is a liver-secreted glycoprotein belonging to the leucine-rich repeat superfamily. It plays a critical role in the endocrine insulin-like growth factor (IGF) system by forming a high-molecular-weight ternary complex of approximately 150 kDa with IGF-1 or IGF-2 and insulin-like growth factor-binding protein-3 (IGFBP-3) or IGFBP-5. This ternary complex restricts the passage of IGFs through the vascular endothelium, thereby extending their circulating half-life and regulating their bioavailability to target tissues. Mutations in the IGFALS gene lead to primary acid-labile subunit deficiency (ACLSD), a rare autosomal recessive disorder characterized by severe reductions in circulating IGF-1 and IGFBP-3, moderate postnatal growth retardation, delayed puberty, and insulin resistance.
While there are currently no approved drugs that directly target IGFALS, its expression is highly regulated by growth hormone (GH). Recombinant human growth hormone (somatropin) indirectly increases IGFALS levels, whereas the GH receptor antagonist pegvisomant decreases them. Additionally, recombinant human IGF-1 (mecasermin) is utilized in clinical management, though patients with complete ALS deficiency show a poor response due to their inability to form the stabilizing ternary complex. Emerging therapeutic strategies, such as RNA interference (RNAi) agents targeting IGFALS, are being explored for the treatment of IGF-driven disorders like acromegaly and certain cancers.
Indirect modulation of expression via growth hormone receptor signaling, and ternary complex formation with recombinant IGF-1 and IGFBP-3
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Insulin-like growth factor-binding protein complex acid-labile subunit (IGFALS).